Angiomax Lyophilisate For Solution For Injection 250Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

Angiomax: Lyophilisate for solution for injection (250mg)

Detailed Information
Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

BIVALIRUDIN is an anticoagulant. It is used in a hospital setting to help prevent blood clots.

In-Depth Information

Angiomax 250mg Powder for Injection

NDC: 652930001
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Heparin-induced Thrombocytopenia, Percutaneous Coronary Intervention (PCI), Unstable Angina

Sometimes used for but not FDA approved for the following conditions:
Acute Myocardial Infarction, Deep Venous Thrombosis (DVT) Prophylaxis

Storage Information
Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees F
Angiomax 250mg Powder for Injection
Close All Sections Show

Reported Side Effects for Angiomax 250mg Powder for Injection

Close Show
Kidney Failure Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Fever Incidence:
<5.0%*
Severity: MILD
Onset: EARLY
Confusion Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Decreased Urination Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Fluid In Lungs Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Fainting Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Rapid Heart Rate Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Bleeding In The Brain Incidence:
<0.1%*
Severity: SEVERE
Onset: DELAYED
Infection Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Upset Stomach Incidence:
0.1-15.0%*
Severity: MILD
Onset: EARLY
Injection Site Reaction Incidence:
0.1-8.0%*
Severity: MILD
Onset: RAPID
Vomiting Incidence:
0.1-6.0%*
Severity: MILD
Onset: EARLY
Bleeding In The Abdomen Incidence:
0.2%*
Severity: SEVERE
Onset: DELAYED
Chest Pain Incidence:
0.2%*
Severity: MODERATE
Onset: EARLY
Headache Incidence:
0.2-12.0%*
Severity: MILD
Onset: EARLY
Low Blood Pressure Incidence:
0.2-12.0%*
Severity: MODERATE
Onset: RAPID
Low Platelet Count Incidence:
0.3-0.7%*
Severity: MODERATE
Onset: DELAYED
Bleeding Incidence:
0.6-13.6%*
Severity: MODERATE
Onset: EARLY
Bruise Incidence:
1.3%*
Severity: MODERATE
Onset: EARLY
Vomiting Of Blood Incidence:
1.3%*
Severity: SEVERE
Onset: DELAYED
Blood In The Urine Incidence:
1.3%*
Severity: MODERATE
Onset: DELAYED
Retaining Urine Incidence:
4.0%*
Severity: MODERATE
Onset: EARLY
Stomach Pain Incidence:
5.0%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
5.0%*
Severity: MILD
Onset: EARLY
Slow Heart Beat Incidence:
5.0%*
Severity: SEVERE
Onset: RAPID
High Blood Pressure Incidence:
6.0%*
Severity: MODERATE
Onset: EARLY
Pelvic Pain Incidence:
6.0%*
Severity: MILD
Onset: DELAYED
Nervousness Incidence:
6.0%*
Severity: MILD
Onset: DELAYED
Inability To Sleep Incidence:
7.0%*
Severity: MILD
Onset: EARLY
Back Pain Incidence:
42.0%*
Severity: MILD
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
Close Show
FIRST Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

SECOND Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

THIRD Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Lactation

Compatible - This drug is generally safe to take by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Angiomax

Close Show

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5